Experimental animal tests have shown that blocking CB1 decreases appetite and may improve the evolution of neurodegenerative and psychiatric diseases (Alzheimer’s disease, schizophrenia, multiple sclerosis). This evidence concerns the gene CNR1 and Alzheimer disease.